Imagery rescripting treatment for OCD and BDD
Imagery Rescripting for Obsessive Compulsive Disorder and Body Dysmorphic Disorder: a Multiple-Baseline Single-Case Experimental Design.
This study is testing a new therapy called imagery rescripting to see if it can help people with Obsessive Compulsive Disorder and Body Dysmorphic Disorder feel better and change their negative thoughts.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 36 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Academic / other |
| Locations | 1 site (Amsterdam-Zuidoost, North Holland) |
| Trial ID | NCT06346301 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of imagery rescripting (ImRs) as a treatment for Obsessive Compulsive Disorder (OCD) and Body Dysmorphic Disorder (BDD) through a multiple baseline case series design. Eighteen participants with OCD and eighteen with BDD will undergo a variable baseline period followed by a series of treatment sessions. The primary focus is on changes in core beliefs and symptoms, measured through various scales and qualitative interviews. The study aims to assess both immediate and longer-term effects of the intervention on patients' mental health.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who meet the DSM-5 criteria for OCD or BDD and have stable medication for at least six weeks.
Not a fit: Patients with current severe mental health issues such as active psychosis or suicidal plans may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce symptoms of OCD and BDD, improving patients' quality of life.
How similar studies have performed: While the approach of imagery rescripting is gaining interest, this specific application for OCD and BDD is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Meet the criteria for OCD or BDD, a primary diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) * Are aged 18 and beyond * Dutch literacy * Cut-off Y-BOCS of 20 * No change in medication. Stable dose at least 6 weeks prior to study. Exclusion Criteria: * Current (hypo)mania * Active suicidal plans * Current psychosis (excluding delusional symptoms related to disorder) * Alcohol or drugs abuse as diagnosed by Diagnostic and Statistical Manual of Mental Disorders (DSM-5) * Electroconvulsive therapy in last 6 months * Neurological disorder or Intelligence Quotient \< 80
Where this trial is running
Amsterdam-Zuidoost, North Holland
- Department of Psychiatry, AMC — Amsterdam-Zuidoost, North Holland, Netherlands (Recruiting)
Study contacts
- Principal investigator: Damiaan Denys, Prof. — Amsterdam UMC
- Study coordinator: Tibor van Verseveld
- Email: t.r.vanverseveld@amsterdamumc.nl
- Phone: +31619624228
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.